Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients
- 15 November 2004
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (22), 4463-4473
- https://doi.org/10.1200/jco.2004.11.035
Abstract
Purpose: To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma.Patients and Methods: Thirty-three patients were treated with EMD 273063, a humanized anti-GD2 monoclonal antibody (mAb) linked to interleukin-2 (IL-2). EMD 273063 was given as a 4-hour intravenous infusion on days 1, 2, and 3 of week 1. Patients with stabilization or regression of disease could receive a second course of treatment at week 5. Dose levels evaluated were 0.8, 1.6, 3.2, 4.8, 6.0, and 7.5 mg/m2/d.Results: Nineteen of 33 patients completed course 1 with stable disease and went on to receive course 2. Eight patients had stable disease on completion of course 2. Grade 3 adverse events included hypophosphatemia (11 patients), hyperglycemia (three patients), hypotension (two patients), thrombocytopenia (one patient), hypoxia (three patients), elevated hepatic transaminases (two patients), and hyperbilirubinemia (one patient). Opioids were required for treatment-associated arthralgias and/or myalgias during 17 of 52 treatment courses. No grade 4 adverse events were observed. Dose-limiting toxicities at the MTD included hypoxia, hypotension, and elevations in AST/ALT. Grade 3 toxicities were anticipated based on prior studies of IL-2 or anti-GD2 mAbs, and all resolved. Immune activation was induced, as measured by lymphocytosis, increased peripheral-blood natural killer activity, and cell numbers, and increased serum levels of the soluble alpha chain of the IL-2 receptor complex.Conclusion: Treatment with the immunocytokine EMD 273063 induced immune activation and was associated with reversible clinical toxicities at the MTD of 7.5 mg/m2/d in melanoma patients.Keywords
This publication has 31 references indexed in Scilit:
- Preclinical and clinical development of immunocytokines.2003
- What does it take to make a natural killer?Nature Reviews Immunology, 2003
- Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody-Interleukin-2 ImmunocytokinePublished by Springer Science and Business Media LLC ,2002
- A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastomaCancer, 1997
- ALTERATION OF THE CD34+Tf-1β CELL LINE PROFILE IN RESPONSE TO LONG-TERM EXPOSURE TO IL-15Cytokine, 1997
- ACTIVATION OF HUMAN EFFECTOR CELLS BY A TUMOR REACTIVE RECOMBINANT ANTI-GANGLIOSIDE GD2 INTERLEUKIN-2 FUSION PROTEINJournal of Immunotherapy, 1996
- Diabetes mellitus induced by low-dose interleukin-2Cancer Immunology, Immunotherapy, 1996
- T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.The Journal of Experimental Medicine, 1996
- Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Addition of interleukin-2in vitro augments detection of lymphokine-activated killer activity generatedin vivoCancer Immunology, Immunotherapy, 1990